European Pharmaceutical Review

MAY 18, 2023

Hepcludex ® (bulevirtide) is the first medicine to be conditionally licensed for chronic hepatitis delta virus (HDV) infection in Great Britain” The National Institute for Health and Care Excellence (NICE) has recommended NHS use of Hepcludex ® (bulevirtide).

88

88

Pharma Times

MARCH 28, 2023

Clinical trial involves patients with liver cirrhosis and hepatic encephalopathy

110

110

ALiEM - Pharm Pearls

JUNE 1, 2023

“Dose adjustment” is recommended by the manufacturer in hepatic dysfunction, but no value is provided [10]. Clinical pearl: Hepatic encephalopathy is a strong contraindication to phenobarbital [9, 10]. Clinical pearl: Hepatic encephalopathy is a strong contraindication to phenobarbital [9, 10].

Inpatient 246

Inpatient Hospitals 246

PharmExec

FEBRUARY 12, 2024

In clinical trials, bepirovirsen showed the potential to address a significant unmet medical need for patients with chronic hepatitis B by reducing hepatitis B surface antigen levels and HBV DNA.

40

40

Pharmaceutical Commerce

FEBRUARY 12, 2024

In clinical trials, bepirovirsen was found to recognize the RNA used by hepatitis B virus to replicate in infected liver cells.

52

52

Pharmaceutical Technology

JUNE 27, 2022

Last Friday, the World Health Organization (WHO) launched updated guidelines for the treatment of hepatitis C , calling for testing and treatment to be delivered in peripheral and community-based facilities and integrating these with available care services.

Vaccines 105

Vaccines 105

ALiEM - Pharm Pearls

JANUARY 22, 2024

Case Question: What clinical condition is associated with eschars? Scrub typhus is often diagnosed clinically based on exposure to endemic regions and its characteristic eschar, which usually appears on the lower extremities, axillae, or genital region. Encephalitis, hepatitis, and pulmonary and cardiac involvement can occur.

Documentation 158

Documentation Hospitals 158

Pharmaceutical Technology

JANUARY 8, 2024

HH-006 is under clinical development by Huahui Health and currently in Phase I for Hepatitis D.

52

52

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement.

111

111

Pharmaceutical Technology

OCTOBER 3, 2023

BW-20507 is under clinical development by Argo Biopharma Australia and currently in Phase II for Hepatitis B.

52

52

ALiEM - Pharm Pearls

DECEMBER 18, 2023

Clinical presentation can be diverse but is usually characterized by a diffuse skin rash, fever, lymphadenopathy, eosinophilia, and internal organ involvement (most commonly the liver). Incidence ranges from 1 in 1,000 to 1 in 10,000 with a mortality rate that can be as high as 10%, and is commonly related to fulminant hepatitis.

Immunity 174

Immunity Immunization 174

European Pharmaceutical Review

OCTOBER 21, 2022

Clinical trial results presented at the US IDWeek conference, revealed a three-dose series of the HEPLISAV-B vaccine prevents hepatitis B virus (HBV) in HIV patients not previously vaccinated against or infected with the virus. It will also evaluate ENGERIX-B, a GSK-manufactured three-dose hepatitis B vaccine series.

Vaccines 77

Vaccines Immunity Immunization 77

European Pharmaceutical Review

NOVEMBER 9, 2022

GSK has announced study results from its Phase IIb trial ( NCT04449029 ) of bepirovirsen for chronic hepatitis B (CHB), indicating that the antisense oligonucleotide therapy could help treat CHB independently or in combination with nucleoside/nucleotide analogues (NAs). Further data on the chronic hepatitis B clinical trial.

88

88

Pharmaceutical Technology

DECEMBER 20, 2023

VTP-300 is under clinical development by Barinthus Biotherapeutics and currently in Phase II for Hepatitis B.

40

40

Pharmaceutical Technology

JANUARY 8, 2024

HH-006 is under clinical development by Huahui Health and currently in Phase I for Hepatitis D.

40

40

Pharmaceutical Technology

OCTOBER 3, 2023

BW-20507 is under clinical development by Argo Biopharma Australia and currently in Phase II for Hepatitis B.

40

40

LifeProNow

MAY 17, 2023

The effectiveness of Veozah to treat moderate to severe hot flashes was demonstrated in each of the first 12-week, randomized, placebo-controlled, double-blind portions of two phase 3 clinical trials. The prescribing information for Veozah includes a warning for elevated hepatic transaminase, or liver injury.

130

130

Pharmacy Times

FEBRUARY 12, 2024

Bepirovirsen is a triple action investigational antisense oligonucleotide and is being evaluated in the B-Well phase 3 clinical trial program for the treatment of chronic hepatitis B.

26

26

Pharmaceutical Technology

NOVEMBER 3, 2022

The US Food and Drug Administration (FDA) has granted approval for the supplemental new drug application (sNDA) of Gilead Sciences ’ Vemlidy (tenofovir alafenamide) to treat chronic hepatitis B virus (HBV) infection in paediatric patients.

52

52

European Pharmaceutical Review

AUGUST 23, 2022

The researchers studied 254 VA patients who were diagnosed with PTSD and hepatitis C between October 1999 and September 2019. Participants received one combination of hepatitis C medications: including glecaprevir and pibrentasvir (GLE/PIB); ledipasvir and sofosbuvir (LDV/SOF); or sofosbuvir and velpatasvir (SOF/VEL). .

Department of Veterans Affairs 72

Department of Veterans Affairs Medical Records Drug Development 72

ALiEM - Pharm Pearls

SEPTEMBER 27, 2023

Acute hepatitis Disulfiram-like reaction with ethanol consumption Pneumonitis from inhalation of spores Seizures from glutamate agonist activity [Image from Canstockphoto] Reveal the Answer 2. This inhibition results in acetaldehyde accumulation and the clinical effects which are termed a disulfiram-like reaction. McGraw-Hill.

Adverse Reactions 166

Adverse Reactions 166

Pharmaceutical Business Review

MARCH 29, 2024

The approval for the expanded indication is backed by findings from a Phase II clinical trial known as Trial 1092. It evaluated Vemlidy in patients aged six to less than 12 years over a 96-week period versus placebo. Effective and tolerable options for children require our best science and a dedicated focus.

Labelling 59

Labelling 59

Pharmaceutical Technology

JULY 5, 2022

Researchers at the UNC School of Medicine have discovered that hepatitis A virus (HAV) replication needs particular interactions between the human protein ZCCHC14 and TENT4 poly(A) polymerases, a group of enzymes. The post UNC team discovers interactions vital for hepatitis A virus replication appeared first on Pharmaceutical Technology.

Compounding 52

Compounding Dosage 52

Med Ed 101

AUGUST 31, 2022

While it can be used for that purpose, it is fairly rare in clinical practice that you see it used for that indication. Lactulose, in my experience, is used more frequently for patients who have hepatic encephalopathy. I will share the most common lactulose clinical pearls that […].

40

40

Pharmafile

MARCH 28, 2023

Published date: 28/03/2023 Summary: - Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpoints - VTP-300 is the first antigen-specific immunotherapy shown to induce sustained reductions in Hepatitis B surface antigen (HBsAg) - Results will be presented at the upcoming European Association for the Study of the Liver (EASL) Congress (..)

Immunity 52

Immunity Immunization 52

European Pharmaceutical Review

MARCH 24, 2023

This treatment decreases hepatic steatosis and circulating lipids. He also shares key data from the ongoing Phase IIb clinical trial, and discusses the broader challenges of developing novel therapies in the NASH space. Data from clinical trials to-date suggests that pegozafermin could reduce hepatic fat and fibrosis.

Drug Development 86

Drug Development 86

Pharmaceutical Technology

JUNE 5, 2023

Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Liver Failure (Hepatic Insufficiency). According to GlobalData, Phase I drugs for Liver Failure (Hepatic Insufficiency) does not have sufficient historical data to build an indication benchmark PTSR for Phase I.

Diabetes 40

Diabetes Drug Development 40

European Pharmaceutical Review

JUNE 27, 2023

Diabetes cell therapy manufacture In Vertex’s first clinical programme, VX-880, recently released data showed all six patients treated with VX-880 engrafted islet cells, produced endogenous insulin (C-peptide). Operated by Lonza, the 130,000 square foot facility is anticipated to create up to 300 new jobs at peak capacity.

Diabetes 95

Diabetes Immunity Immunization 95

pharmaphorum

MARCH 10, 2022

Advance Combination Therapies, Outline Clinical Endpoints & Understand the Immunology Perspective to Achieve Functional Cures for Chronic Hepatitis B. This industry-orientated forum is timely positioned after EASL to reset standards after the latest readouts. Access the official agenda for more information.

Drug Development 52

Drug Development Immunity Immunization Vaccines 52

LifeProNow

MARCH 10, 2023

ZAVZPRET was well tolerated in clinical trials. Hypersensitivity reactions, including facial swelling and urticaria, have occurred with ZAVZPRET in clinical studies. Use in Specific Populations: Hepatic Impairment : Avoid use in patients with severe hepatic impairment.

Adverse Reactions 100

Adverse Reactions 100

Pharmaceutical Technology

MAY 10, 2023

XinThera’s therapy targeting MK2 is expected to enter clinical trials later in 2023. By adding an additional pipeline targeting oncology and inflammation diseases, the company expects that the deal will complement its existing clinical development priorities.

Immunity 52

Immunity Immunization 52

pharmaphorum

JULY 26, 2022

The Hepatitis B (HBV) vaccine and human papillomavirus (HPV) vaccines are key examples. For Christopher Oelkrug, Director of Business Development for Advanced Clinical, it’s an exciting time to investigate the clinical efficacy of therapeutic cancer vaccines.

Vaccines 52

Vaccines Immunity Immunization 52

European Pharmaceutical Review

SEPTEMBER 20, 2022

Zuranolone is an investigational oral 14-day treatment under clinical development for adult patients with MDD and postpartum depression. Zuranolone was generally well-tolerated with a safety profile consistent with prior clinical studies. Can Hepatitis C drugs reduce symptoms of PTSD?

Labelling 88

Labelling 88

European Pharmaceutical Review

FEBRUARY 23, 2023

Meg Doherty, Director of WHO’s Global HIV, Hepatitis and Sexually Transmitted Infections Programmes in Geneva welcomed the results of the D2EFT study. For more than three million people living with HIV worldwide for whom first-line HIV treatment does not work, there is now evidence to support a range of treatment options.

93

93

Pharmaceutical Technology

MARCH 4, 2023

Vebreltinib is under clinical development by Apollomics and currently in Phase II for Solid Tumor. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The therapeutic candidate is administered orally as a capsule.

Drug Development 40

Drug Development 40

Pharmaceutical Technology

MARCH 4, 2023

Vebreltinib is under clinical development by Apollomics and currently in Phase II for Renal Cell Carcinoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The therapeutic candidate is administered orally as a capsule.

Drug Development 40

Drug Development 40

Pharmaceutical Technology

MARCH 4, 2023

Vebreltinib is under clinical development by Apollomics and currently in Phase II for Non-Small Cell Lung Cancer. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The therapeutic candidate is administered orally as a capsule.

Drug Development 40

Drug Development 40